EichorEICHOR
Location: Verdun Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Verdun

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Phase 3 · Gilead Sciences · NCT06051617Spatial Memory Training and Cognitive Function
NA · Douglas Mental Health University Institute · Douglas Mental Health University Institute · NCT07002996Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associate
Phase 3 · Local Institution - 1601 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT05980949Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown O
Phase 3 · Investigational Site Number : 1240004 · Sanofi · NCT05263206Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia
NA · McGill Lab for Computational Psychiatry and Translation - Bu · Douglas Mental Health University Institute · NCT07428460Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe At
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06947993A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by
Phase 2/Phase 3 · McGill Center for Studies in Aging · Washington University School of Medicine · NCT05552157Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic A
NA · CH de Verdun · Hospices Civils de Lyon · NCT03290456Management of COPD Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exac
NA · Centre Hospitalier Verdun · Biosency · NCT06523140Impact of an Early and Extended Rehabilitation Program Combining Individually Tailored Nutrition and Physical Activities
NA · CH de Verdun · Nantes University Hospital · NCT06581939A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT
Phase 3 · Local Institution - 1601 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT06126224A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by
Phase 2/Phase 3 · McGill Center for Studies in Aging · Washington University School of Medicine · NCT06647498Remibrutinib Open Label Roll-over Post-trial Access Protocol
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT07456891Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Phase 3 · Sima Recherche · Bristol-Myers Squibb · NCT07116967Modifying PEST for Psoriatic Arthritis Screening
NA · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06382051Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Phase 3 · Investigative Site CA029 · Incyte Corporation · NCT06855498Dominantly Inherited Alzheimer Network (DIAN)
Phase N/A · McGill University Research Centre for Studies in Aging · Washington University School of Medicine · NCT00869817A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase 2 · SIMa Recherche · Eli Lilly and Company · NCT07533019A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Phase 2 · SIMa Recherche · Eli Lilly and Company · NCT07533006
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.